Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways

US10869872B2 · kind B2 · utility

Assignee

• Asana BioSciences, LLC · US

Inventors

• Scott K. Thompson · Phoenixville, US
• Roger Smith · Madison, US
• Sanjeeva P. Reddy · Chester Springs, US
• Tyler M. John · Phoenixville, US
• Vijay Kumar Nyavanandi · Hyderabad, IN
• Subramanya Hosahalli · Bengaluru, IN
• Vijay Potluri · Hyderabad, IN
• Sunil Kumar Panigrahi · Dashapalla, IN
• Prabhakara Rao Nadipalli · Secunderabad, IN
• Saumitra Sengupta · Basel, CH

Key dates

• Filing date: Jan 24, 2019
• Grant date: Dec 22, 2020
• Expiry date: Jan 24, 2039

Classification

• Technology area (CPC —): General

Abstract

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.